NYSEAMERICAN:MAIA MAIA Biotechnology (MAIA) Stock Price, News & Analysis → get a piece of the profit from this land (From True Market Insiders) (Ad) Free MAIA Stock Alerts $3.31 +0.19 (+6.09%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$3.00▼$3.4350-Day Range N/A52-Week Range$0.82▼$3.59Volume424,011 shsAverage Volume315,952 shsMarket Capitalization$72.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get MAIA Biotechnology alerts: Email Address MAIA Biotechnology MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish6.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.98Based on 4 Articles This WeekInsider TradingAcquiring Shares$239,920 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.17 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for MAIA Biotechnology.Read more about MAIA Biotechnology's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.30% of the float of MAIA Biotechnology has been sold short.Short Interest Ratio / Days to CoverMAIA Biotechnology has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MAIA Biotechnology has recently increased by 28.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMAIA Biotechnology does not currently pay a dividend.Dividend GrowthMAIA Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MAIA. Previous Next 1.1 News and Social Media Coverage News SentimentMAIA Biotechnology has a news sentiment score of -0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for MAIA Biotechnology this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for MAIA on MarketBeat in the last 30 days. This is a decrease of -95% compared to the previous 30 days.MarketBeat Follows3 people have added MAIA Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MAIA Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $239,920.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders36.98% of the stock of MAIA Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.65% of the stock of MAIA Biotechnology is held by institutions.Read more about MAIA Biotechnology's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of MAIA Biotechnology is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MAIA Biotechnology is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About MAIA Biotechnology Stock (NYSEAMERICAN:MAIA)MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.Read More MAIA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MAIA Stock News HeadlinesApril 27, 2024 | insidertrades.comMAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ngar Yee Louie Acquires 19,665 SharesMay 17 at 8:37 AM | businesswire.comMAIA Biotechnology to Present at the BIO International Convention 2024May 16 at 8:37 AM | businesswire.comMAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual MeetingMay 15 at 11:20 AM | investorplace.comMAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024April 30, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private PlacementApril 29, 2024 | marketwatch.comMAIA Biotechnology Shares Hit 52-Week High After Director Stock PurchaseApril 29, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private PlacementApril 28, 2024 | finance.yahoo.comMAIA Biotechnology, Inc. (MAIA)April 23, 2024 | businesswire.comMAIA Biotechnology Announces $1.00 Million Private PlacementApril 5, 2024 | businesswire.comMAIA Biotechnology to Present at Two Investor Conferences in April 2024April 4, 2024 | msn.comeFFECTOR shelves tomivosertib in NSCLC following Phase II failureMarch 28, 2024 | investing.comMAIA Biotechnology directors buy shares amid development pushMarch 28, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro GuerreroMarch 26, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private PlacementMarch 26, 2024 | businesswire.comMAIA Biotechnology Announces $1.33 Million Private PlacementMarch 22, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private PlacementMarch 21, 2024 | businesswire.comMAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory BoardMarch 16, 2024 | finance.yahoo.comDirector Ngar Louie Acquires 170,940 Shares of MAIA Biotechnology Inc (MAIA)March 14, 2024 | msn.comMAIA Biotechnology rises 3% on $2.92M private placementMarch 7, 2024 | finance.yahoo.comMAIA Biotechnology to Participate in the 36th Annual ROTH ConferenceMarch 7, 2024 | investing.comMAIA Biotechnology nears end of Phase 2 cancer trialMarch 6, 2024 | markets.businessinsider.comMAIA Announces Positive Data From Phase 2 THIO Clinical Trial For NSCLC; Stock Rises 8%March 6, 2024 | finance.yahoo.comMAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual MeetingMarch 6, 2024 | businesswire.comMAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual MeetingMarch 6, 2024 | businesswire.comMAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer PatientsSee More Headlines Receive MAIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MAIA Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:MAIA CUSIPN/A CIKN/A Webwww.MAIABiotech.com Phone312-416-8592FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-2,189.07% Return on Assets-282.82% Debt Debt-to-Equity RatioN/A Current Ratio1.77 Quick Ratio1.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.26) per share Price / Book-12.73Miscellaneous Outstanding Shares21,840,000Free Float13,762,000Market Cap$72.29 million OptionableNot Optionable Beta0.04 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Vlad Vitoc M.B.A. (Age 53)M.D., Co-Founder, President, CEO & Chairman of the Board of Directors Comp: $715.55kDr. Sergei M. Gryaznov Ph.D. (Age 64)Chief Scientific Officer Comp: $524.77kMr. Jeffrey C. HimmelreichHead of FinanceLinda MoreiraCompany SecretaryKey CompetitorsAnebulo PharmaceuticalsNASDAQ:ANEBImmix BiopharmaNASDAQ:IMMXEledon PharmaceuticalsNASDAQ:ELDNCalciMedicaNASDAQ:CALCTiziana Life SciencesNASDAQ:TLSAView All CompetitorsInsidersNgar Yee LouieBought 19,665 shares on 4/25/2024Total: $39,919.95 ($2.03/share)Stan SmithBought 170,940 shares on 3/14/2024Total: $199,999.80 ($1.17/share)Ramiro GuerreroBought 1,200 shares on 5/18/2023Total: $2,964.00 ($2.47/share)View All Insider Transactions MAIA Stock Analysis - Frequently Asked Questions Are investors shorting MAIA Biotechnology? MAIA Biotechnology saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 1,010,000 shares, an increase of 28.6% from the April 15th total of 785,200 shares. Based on an average daily trading volume, of 355,400 shares, the short-interest ratio is presently 2.8 days. Currently, 6.3% of the shares of the stock are sold short. View MAIA Biotechnology's Short Interest. How were MAIA Biotechnology's earnings last quarter? MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) posted its quarterly earnings data on Thursday, March, 21st. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.06. How do I buy shares of MAIA Biotechnology? Shares of MAIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:MAIA) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingObama’s Forever Term [exposed]Porter & Company4 Cryptos BETTER than BitcoinTrue Market InsidersElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MAIA Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
